Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension

chanyun kim, Samin Hong, Gong Je Seong

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: The aim of this study was to evaluate the efficacy and safety of brimonidine 0.2% versus brimonidine Purite 0.15% in Asians with ocular hypertension. Methods: This study was a prospective, randomized, observer-masked, short-term crossover trial. Eighty-six (86) Asian subjects with newly diagnosed ocular hypertension were randomly assigned to receive either brimonidine 0.2% or brimonidine Purite 0.15%, both dosed twice a day for 4 weeks. Subjects were then washed out for 6 weeks and switched to the opposite treatment for 4 weeks. Results: The baseline intraocular pressure (IOP) was 24.4 ± 2.45 mmHg for brimonidine 0.2% and 24.39 ± 2.56 mmHg for brimonidine Purite 0.15% (P = 0.985). The IOP was at trough drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% therapy were 20.10 ± 2.01 mmHg and 21.00 ± 1.67 mmHg (P = 0.001), respectively. The IOP at peak drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% treatment were 18.10 ± 1.73 mmHg and 18.20 ± 1.71 mmHg (P = 0.518), respectively. Brimonidine 0.2% was found to cause more allergic conjunctivitis than brimonidine Purite 0.15% (P < 0.001). Conclusions: Brimonidine 0.2% has a higher potency of lowering IOP than brimonidine Purite 0.15% at trough when used twice-daily. However, ocular allergic reaction was more frequent and severe with brimonidine 0.2% than with brimonidine Purite 0.15%.

Original languageEnglish
Pages (from-to)481-486
Number of pages6
JournalJournal of Ocular Pharmacology and Therapeutics
Volume23
Issue number5
DOIs
Publication statusPublished - 2007 Oct 1

Fingerprint

Ocular Hypertension
Intraocular Pressure
Brimonidine Tartrate
Allergic Conjunctivitis

All Science Journal Classification (ASJC) codes

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{ecd423a93885483daf177f60811f50e1,
title = "Brimonidine 0.2{\%} versus brimonidine purite 0.15{\%} in Asian ocular hypertension",
abstract = "Purpose: The aim of this study was to evaluate the efficacy and safety of brimonidine 0.2{\%} versus brimonidine Purite 0.15{\%} in Asians with ocular hypertension. Methods: This study was a prospective, randomized, observer-masked, short-term crossover trial. Eighty-six (86) Asian subjects with newly diagnosed ocular hypertension were randomly assigned to receive either brimonidine 0.2{\%} or brimonidine Purite 0.15{\%}, both dosed twice a day for 4 weeks. Subjects were then washed out for 6 weeks and switched to the opposite treatment for 4 weeks. Results: The baseline intraocular pressure (IOP) was 24.4 ± 2.45 mmHg for brimonidine 0.2{\%} and 24.39 ± 2.56 mmHg for brimonidine Purite 0.15{\%} (P = 0.985). The IOP was at trough drug effect after 4 weeks of brimonidine 0.2{\%} and brimonidine Purite 0.15{\%} therapy were 20.10 ± 2.01 mmHg and 21.00 ± 1.67 mmHg (P = 0.001), respectively. The IOP at peak drug effect after 4 weeks of brimonidine 0.2{\%} and brimonidine Purite 0.15{\%} treatment were 18.10 ± 1.73 mmHg and 18.20 ± 1.71 mmHg (P = 0.518), respectively. Brimonidine 0.2{\%} was found to cause more allergic conjunctivitis than brimonidine Purite 0.15{\%} (P < 0.001). Conclusions: Brimonidine 0.2{\%} has a higher potency of lowering IOP than brimonidine Purite 0.15{\%} at trough when used twice-daily. However, ocular allergic reaction was more frequent and severe with brimonidine 0.2{\%} than with brimonidine Purite 0.15{\%}.",
author = "chanyun kim and Samin Hong and Seong, {Gong Je}",
year = "2007",
month = "10",
day = "1",
doi = "10.1089/jop.2007.0042",
language = "English",
volume = "23",
pages = "481--486",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension. / kim, chanyun; Hong, Samin; Seong, Gong Je.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 23, No. 5, 01.10.2007, p. 481-486.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Brimonidine 0.2% versus brimonidine purite 0.15% in Asian ocular hypertension

AU - kim, chanyun

AU - Hong, Samin

AU - Seong, Gong Je

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Purpose: The aim of this study was to evaluate the efficacy and safety of brimonidine 0.2% versus brimonidine Purite 0.15% in Asians with ocular hypertension. Methods: This study was a prospective, randomized, observer-masked, short-term crossover trial. Eighty-six (86) Asian subjects with newly diagnosed ocular hypertension were randomly assigned to receive either brimonidine 0.2% or brimonidine Purite 0.15%, both dosed twice a day for 4 weeks. Subjects were then washed out for 6 weeks and switched to the opposite treatment for 4 weeks. Results: The baseline intraocular pressure (IOP) was 24.4 ± 2.45 mmHg for brimonidine 0.2% and 24.39 ± 2.56 mmHg for brimonidine Purite 0.15% (P = 0.985). The IOP was at trough drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% therapy were 20.10 ± 2.01 mmHg and 21.00 ± 1.67 mmHg (P = 0.001), respectively. The IOP at peak drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% treatment were 18.10 ± 1.73 mmHg and 18.20 ± 1.71 mmHg (P = 0.518), respectively. Brimonidine 0.2% was found to cause more allergic conjunctivitis than brimonidine Purite 0.15% (P < 0.001). Conclusions: Brimonidine 0.2% has a higher potency of lowering IOP than brimonidine Purite 0.15% at trough when used twice-daily. However, ocular allergic reaction was more frequent and severe with brimonidine 0.2% than with brimonidine Purite 0.15%.

AB - Purpose: The aim of this study was to evaluate the efficacy and safety of brimonidine 0.2% versus brimonidine Purite 0.15% in Asians with ocular hypertension. Methods: This study was a prospective, randomized, observer-masked, short-term crossover trial. Eighty-six (86) Asian subjects with newly diagnosed ocular hypertension were randomly assigned to receive either brimonidine 0.2% or brimonidine Purite 0.15%, both dosed twice a day for 4 weeks. Subjects were then washed out for 6 weeks and switched to the opposite treatment for 4 weeks. Results: The baseline intraocular pressure (IOP) was 24.4 ± 2.45 mmHg for brimonidine 0.2% and 24.39 ± 2.56 mmHg for brimonidine Purite 0.15% (P = 0.985). The IOP was at trough drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% therapy were 20.10 ± 2.01 mmHg and 21.00 ± 1.67 mmHg (P = 0.001), respectively. The IOP at peak drug effect after 4 weeks of brimonidine 0.2% and brimonidine Purite 0.15% treatment were 18.10 ± 1.73 mmHg and 18.20 ± 1.71 mmHg (P = 0.518), respectively. Brimonidine 0.2% was found to cause more allergic conjunctivitis than brimonidine Purite 0.15% (P < 0.001). Conclusions: Brimonidine 0.2% has a higher potency of lowering IOP than brimonidine Purite 0.15% at trough when used twice-daily. However, ocular allergic reaction was more frequent and severe with brimonidine 0.2% than with brimonidine Purite 0.15%.

UR - http://www.scopus.com/inward/record.url?scp=36749034325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749034325&partnerID=8YFLogxK

U2 - 10.1089/jop.2007.0042

DO - 10.1089/jop.2007.0042

M3 - Article

VL - 23

SP - 481

EP - 486

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 5

ER -